Safety and therapeutic effect of mesenchymal stem cell infusion on moderate to severe ulcerative colitis

Abstract

One of the primary targets of the clinical treatment of ulcerative colitis (UC) is to repair the damaged colonic mucosa. Mesenchymal stem cells (MSCs) have therapeutic potential in regenerative medicine due to their differentiation capacity and their secretion of numerous bioactive molecules. The present study describes a clinical trial (trial registration no. NCT01221428) investigating the safety and therapeutic effect of MSCs derived from human umbilical cord on moderate to severe UC. Thirty-four patients with UC were included in group <i>I</i> and treated with MSC infusion in addition to the base treatment, and thirty-six patients were in group <i>II</i> and treated with normal saline in addition to the base treatment. One month after therapy, 30/36 patients in group <i>I</i> showed good response, and diffuse and deep ulcer formation and severe inflammatory mucosa were improved markedly. During the follow up, the median Mayo score and histology score in group <i>I</i> were decreased while IBDQ scores were significantly improved compared with before treatment and group <i>II (P<0.05)</i>. Compared with group <i>II</i>, there were no evident adverse reactions after MSC infusion in any of the patients in group <i>I</i>, and no chronic side effects or lingering effects appeared during the follow-up period. In conclusion, MSC infusion might be a useful and safe therapy for treating UC.